News Room
News Releases
Aug. 01, 2019 Finances
Posted Conference Call for Q1 FY2019 [Webcast]
Jul. 31, 2019 (PDF/123KB) R&D
Sumitomo Dainippon Pharma Submits New Drug Application for Approval of Manufacturing and Marketing for Lurasidone in Japan for the Treatment of Schizophrenia and Bipolar Depression
Jul. 31, 2019 (PDF/173KB) R&D
Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder
Jul. 29, 2019 (PDF/582KB) Finances
Presentation Material (First Quarter Financial Results for FY2019)
Jul. 29, 2019 (PDF/457KB) Finances
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2020
Jul. 29, 2019 (PDF/301KB) Finances
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2020 [IFRS]
Jul. 29, 2019 (PDF/139KB) Finances
Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
Jul. 25, 2019 (PDF/151KB) CSR
Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment and FTSE Blossom Japan Index
Jul. 25, 2019 (PDF/109KB) Corporate
Sumitomo Dainippon Pharma to Enter Into an Investment Agreement with Drawbridge Health
Jul. 22, 2019 (PDF/240KB) R&D
Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Clinical Study of LONASEN, an Atypical Antipsychotic Agent, in the Treatment of Adolescent Patients with Schizophrenia in Japan
Documents for Press
Dec. 02, 2013 (PDF/414KB) R&D
Presentation material of press conference (Healios and DSP: Alliance for Japanese market-iPS cell technology into practical use-)